降脂护肝系列胶囊治疗非酒精性脂肪性肝炎的临床研究

目的：观察降脂护肝系列胶囊治疗非酒精性脂肪性肝炎的临床疗效。方法：治疗组100例,采用辨证分型与辨病相结合的方法,分别用降脂护肝Ⅰ、Ⅱ、Ⅲ号胶囊治疗;对照组60例用烟酸肌醇脂片及肝泰乐治疗。两组均用药8周,治疗期间不予其他护肝、降酶和降血脂类药物,观察治疗前后患者血清ALT、AST、TCh、TG、PⅢP、LN、HA、Ⅳ-C的变化,肝脏B超或CT的结果变化以及临床症状、体征的变化。结果：治疗组的临床显效率为65%,对照组为35（,差异有非常显著性意义（P〈0.01）。治疗组总有效率94（,对照组为58.3（,差异有显著性意义（P〈0.05）;治疗组治疗前后ALT、AST、TCh、TG、PⅢP、LN、HA、Ⅳ-C等生化检测结果比较,差异有非常显著性意义（P〈0.01）。治疗后两组ALT、GGT、TCh、TG等值比较,差异有非常显著性意义（P〈0.01）。结论：降脂护肝胶囊治疗非酒精性脂肪性肝炎疗效良好,有护肝、降酶和抗肝纤维化作用。

Clinical observation of treatment with serial Jiangzhi Hugan capsule on nonalcoholic steatohepatitis

Objective：To observe the clinical effect of serial Jiangzhi Hugan capsule（JZHGC）on nonalcoholic steatohepatitis（NASH）.Methods：One hundred patients in the treatment group were given JZHGCⅠ,Ⅱ and Ⅲ respectively on the basis of syndrome differentiation combined with disease differentiation;Sixty patients in the control group was treated with tabellae inositoli nicotinatis and glucuro lactone tablets.After they were treated for 8 weeks without other drugs for protecting liver function,reducing aminotransferase and lowering lipid.Changes of ALT,AST,TCh,TG,PⅢP,LN,HA,Ⅳ-C,B-ultrasound,CT,clinical symptoms and signs before and after treatment were observed.Results：The distinct effective rate in the treatment group and in the control group were 65% and 35% respectively（P 0.01）;The total effective rate in the treatment group and in the control group were 94% and 58.3 %respectively;There were also significant differences in ALT,GGT,TCh,TG between the two groups after treatment（P 0.01）.After treatment,changes of biochemical items such as ALT,AST,TBil,TCh,TG,PⅢP,LN,HA,Ⅳ-C in the treatment group were significant（P 0.01）.Conclusion： JZHGC can protect liver function,reduce aminotransferase and treat liver fibrosis.